DS and new clinical trials for AML

[Guest guest]

was treated 7 years ago for AML and the treatement lasted about 6 months.

Looks like they have new clinical trials going which last a bit longer:

Is anyone of the list receiving this newer clinical trial?

http://www.cancer.gov/search/viewclinicaltrials.aspx?version=healthprofessional & cdrid=487497

Arm I (standard therapy):

Induction 1: Patients receive cytarabine IT at the time of diagnosis or on day 1*. Patients also receive cytarabine IV on days 1-10, daunorubicin hydrochloride IV over 6 hours on days 1, 3, and 5, and etoposide IV over 4 hours on days 1-5. After 3 weeks of rest, all patients (regardless of remission status) proceed to induction 2. [Note: *Patients with CNS disease receive cytarabine IT twice weekly until the cerebrospinal fluid is clear, followed by two additional IT treatments. Patients with refractory CNS leukemia after 6 doses of IT treatment are removed from the study.]

Induction 2: Patients receive cytarabine IT on day 1, cytarabine IV on days 1-8, daunorubicin hydrochloride IV over 6 hours on days 1, 3, and 5, and etoposide IV over 4 hours on days 1-5. After 3 weeks of rest, patients in complete remission (CR) proceed to intensification 1. Patients with refractory disease are removed from protocol therapy.

Intensification 1: Patients receive cytarabine IT on day 1, high-dose cytarabine IV over 1 hour on days 1-5, and etoposide IV over 1 hour on days 1-5. After 3 weeks of rest, patients in remission proceed to intensification 2, followed by intensification 3. Patients in remission proceed to allogeneic SCT 2-8 weeks after blood counts recover. Patients with high-risk disease with an alternative donor proceed to intensification 2 and 3, followed by allogeneic SCT. Patients not in remission are removed from protocol therapy.

Intensification 2: Patients receive cytarabine IT on day 1, high-dose cytarabine IV over 2 hours on days 1-4, and mitoxantrone hydrochloride IV over 1 hour on days 3-6. After 3 weeks of rest, patients proceed to intensification 3.

Intensification 3: Patients receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, and 9 and asparaginase intramuscularly on days 2 and 9.

http://www.cancer.gov/cancertopics/pdq/treatment/childAML/HealthProfessional/page9

[Guest guest]

That protocol is quite different than what it was when did

therapy 9 yrs ago. I wonder why they changed it?

From:

[mailto: ] On Behalf

Of Pearson

Sent: Saturday, February 27, 2010 7:18 AM

Subject: [ ] DS and new clinical trials for AML

was treated 7 years ago for AML and the treatement

lasted about 6 months.

Looks like they have new clinical trials going which last

a bit longer:

Is anyone of the list receiving this newer clinical trial?

http://www.cancer.gov/search/viewclinicaltrials.aspx?version=healthprofessional & cdrid=487497

Arm I (standard therapy):

Induction 1: Patients

receive cytarabine IT at the time of diagnosis or on day 1*. Patients

also receive cytarabine IV on days 1-10, daunorubicin hydrochloride IV

over 6 hours on days 1, 3, and 5, and etoposide IV over 4 hours on days

1-5. After 3 weeks of rest, all patients (regardless of remission

status) proceed to induction 2.

[Note: *Patients

with CNS disease receive cytarabine IT twice weekly until the cerebrospinal

fluid is clear, followed by two additional IT treatments. Patients with

refractory CNS leukemia after 6 doses of IT treatment are removed from the

study.]

Induction 2: Patients

receive cytarabine IT on day 1, cytarabine IV on days 1-8, daunorubicin

hydrochloride IV over 6 hours on days 1, 3, and 5, and etoposide IV over

4 hours on days 1-5. After 3 weeks of rest, patients in complete

remission (CR) proceed to intensification 1. Patients with refractory

disease are removed from protocol therapy.

Intensification 1: Patients

receive cytarabine IT on day 1, high-dose cytarabine IV over 1 hour on

days 1-5, and etoposide IV over 1 hour on days 1-5. After 3 weeks of

rest, patients in remission proceed to intensification 2, followed by

intensification 3. Patients in remission proceed to allogeneic SCT 2-8

weeks after blood counts recover. Patients with high-risk disease with

an alternative donor proceed to intensification 2 and 3, followed by

allogeneic SCT. Patients not in remission are removed from protocol

therapy.

Intensification 2: Patients

receive cytarabine IT on day 1, high-dose cytarabine IV over 2 hours on

days 1-4, and mitoxantrone hydrochloride IV over 1 hour on days 3-6.

After 3 weeks of rest, patients proceed to intensification 3.

Intensification 3: Patients

receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, and 9 and

asparaginase intramuscularly on days 2 and 9.

http://www.cancer.gov/cancertopics/pdq/treatment/childAML/HealthProfessional/page9